<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="313">
  <stage>Registered</stage>
  <submitdate>29/08/2005</submitdate>
  <approvaldate>5/09/2005</approvaldate>
  <actrnumber>ACTRN12605000297628</actrnumber>
  <trial_identification>
    <studytitle>The effect of CoEnzymeQ10 on vascular function in type 2 diabetes mellitus: a pilot study.</studytitle>
    <scientifictitle>The effect of CoEnzymeQ10 on vascular function in type 2 diabetes mellitus: a pilot study.</scientifictitle>
    <utrn />
    <trialacronym>Pilot CoQ</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 diabetes and impaired vascular endothelial function (measured by flow-mediated vasodilatation (FMD) of brachial artery using ultrasound).</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>An open-label non-randomised sequential pilot trial.  Whilst continuing on their usual medications (which may include lipid-lowering and/or antihypertensive therapies), eligible subjects are supplemented with oral CoEnzymeQ10 (CoQ) 200mg daily for four weeks (supplementation period 1).  Following this, CoQ supplementation is ceased for four weeks (washout period - no placebo given), before being restarted at the same dose for a further four weeks (supplementation period 2).  </interventions>
    <comparator> There is no separate comparison group (analysis by paired comparison of changes in primary outcome on and off CoQ supplementation) and sequential treatment order is identical for all subjects.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in flow-mediated vasodilation (FMD) of brachial artery, measured by ultrasound.</outcome>
      <timepoint>Measurements will be performed at baseline (week 0), at end of supplementation period 1 (week 4), at end of washout (week 8) and at end of supplementation 2 (week 12).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Endothelium-independent nitrate-mediated brachial artery dilatation (NMD), measured by ultrasound; large (C1) and small (C2) artery compliance, measured by non-invasive radial pulse wave analysis (PulseWave CR-2000 system, HDI).</outcome>
      <timepoint>Measured at weeks 0, 4, 8 and 12.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adult subjects with type 2 diabetes with screening FMD of &lt;5%, who were able to provide informed consent.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Uncontrolled glycaemia (HbA1c 9.0% or greater); daytime insulin use; advanced renal impairment (serum creatinine&gt;300umol/L); clinical cardiac failure; recent vascular event (acute myocardial infarction or stroke within preceding three months).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>Sequential</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>2/11/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Gerald F Watts</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>School of Medicine and Pharmacology, University of Western Australia (Royal Perth Hospital Unit) internal departmental funds</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Blackmores</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This pilot (preliminary) study aims to determine if taking supplements of CoEnzymeQ10 (a vitamin with antioxidant properties) improves the relaxation function of artery blood vessels in people with type 2 diabetes.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Gerald F Watts</name>
      <address>GPO Box X2213  PERTH  WA  6847</address>
      <phone>+61 8 92240248</phone>
      <fax>+61 8 92240246</fax>
      <email>gfwatts@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Mary-Ann Powell</name>
      <address>GPO Box X2213, PERTH  WA  6847</address>
      <phone>+61 8 92240244</phone>
      <fax>+61 8 92240243</fax>
      <email>powell@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>